Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...